Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer.

Schöder HM, Demétrio De Souza França P, Nakajima R, Burnazi EM, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein R, Lyashchenko SK, Lewis JS, O'Donoghue JA, Ganly I, Patel SG, Lee NY, Reiner T.

Clin Cancer Res. 2020 Apr 3. pii: clincanres.3484.2019. doi: 10.1158/1078-0432.CCR-19-3484. [Epub ahead of print]

2.

First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.

Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS.

J Nucl Med. 2020 Mar 13. pii: jnumed.119.234864. doi: 10.2967/jnumed.119.234864. [Epub ahead of print]

PMID:
32169913
3.

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.

Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MP, Chabon JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M, Abu-Akeel M, Plodkowski AJ, Perez-Johnston R, Yoo CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T, Li BT, Alizadeh AA, Diehn M.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.3418.2019. doi: 10.1158/1078-0432.CCR-19-3418. [Epub ahead of print]

PMID:
32046999
4.

The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction.

Inda MC, Joshi S, Wang T, Bolaender A, Gandu S, Koren Iii J, Che AY, Taldone T, Yan P, Sun W, Uddin M, Panchal P, Riolo M, Shah S, Barlas A, Xu K, Chan LYL, Gruzinova A, Kishinevsky S, Studer L, Fossati V, Noggle SA, White JR, de Stanchina E, Sequeira S, Anthoney KH, Steele JW, Manova-Todorova K, Patil S, Dunphy MP, Pillarsetty N, Pereira AC, Erdjument-Bromage H, Neubert TA, Rodina A, Ginsberg SD, De Marco Garcia N, Luo W, Chiosis G.

Nat Commun. 2020 Jan 16;11(1):319. doi: 10.1038/s41467-019-14082-5.

5.

Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS.

Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007. Epub 2019 Oct 24.

PMID:
31668946
6.

Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.

Grkovski M, Goel R, Krebs S, Staton KD, Harding JJ, Mellinghoff IK, Humm JL, Dunphy MPS.

J Nucl Med. 2020 Mar;61(3):357-366. doi: 10.2967/jnumed.119.229740. Epub 2019 Oct 10.

PMID:
31601700
7.

Chaperome heterogeneity and its implications for cancer study and treatment.

Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G.

J Biol Chem. 2019 Feb 8;294(6):2162-2179. doi: 10.1074/jbc.REV118.002811. Epub 2018 Nov 8. Review.

8.

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.

Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS.

Radiology. 2018 May;287(2):667-675. doi: 10.1148/radiol.2017162610. Epub 2018 Jan 31.

9.

Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans.

Mahajan S, Dunphy MP, Haque S, Pandit-Taskar N.

Clin Nucl Med. 2018 Jan;43(1):19-22. doi: 10.1097/RLU.0000000000001892.

PMID:
29135612
10.

Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Kim MM, Parolia A, Dunphy MP, Venneti S.

Nat Rev Clin Oncol. 2016 Dec;13(12):725-739. doi: 10.1038/nrclinonc.2016.108. Epub 2016 Jul 19. Review.

11.

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.

12.

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.

Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV.

J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.

13.

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB.

Sci Transl Med. 2015 Feb 11;7(274):274ra17. doi: 10.1126/scitranslmed.aaa1009.

14.

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G.

Expert Opin Investig Drugs. 2014 May;23(5):611-28. doi: 10.1517/13543784.2014.902442. Epub 2014 Mar 26. Review.

15.

Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm.

Nitadori J, Bograd AJ, Morales EA, Rizk NP, Dunphy MP, Sima CS, Rusch VW, Adusumilli PS.

Ann Surg Oncol. 2013 Dec;20(13):4282-8. doi: 10.1245/s10434-013-3212-2. Epub 2013 Aug 17.

16.

FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW, Adusumilli PS.

Ann Surg Oncol. 2012 Oct;19(11):3598-605. doi: 10.1245/s10434-012-2414-3. Epub 2012 May 30.

17.

High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Adusumilli PS.

J Thorac Oncol. 2012 Jul;7(7):1192-7. doi: 10.1097/JTO.0b013e3182519d96.

18.

Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S.

Mol Imaging Biol. 2012 Feb;14(1):25-31. doi: 10.1007/s11307-010-0462-2.

19.

Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Dunphy MP, Lewis JS.

J Nucl Med. 2009 May;50 Suppl 1:106S-21S. doi: 10.2967/jnumed.108.057281. Epub 2009 Apr 20. Review.

20.

In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research.

Dunphy MP, Entenberg D, Toledo-Crow R, Larson SM.

Microvasc Res. 2009 Jun;78(1):51-6. doi: 10.1016/j.mvr.2009.03.008. Epub 2009 Apr 9.

21.

Molecular imaging of atherosclerosis.

Dunphy MP, Strauss HW.

Curr Cardiol Rep. 2008 Mar;10(2):121-7. Review.

PMID:
18417012
22.

Radionuclide techniques for identifying vulnerable plaque.

Dunphy MP, Schoder H, Strauss HW.

J Nucl Med. 2007 Nov;48(11):1753-5. No abstract available.

23.

Association of vascular 18F-FDG uptake with vascular calcification.

Dunphy MP, Freiman A, Larson SM, Strauss HW.

J Nucl Med. 2005 Aug;46(8):1278-84.

24.

A postdischarge adverse drug reaction capture mechanism using medical record technicians.

Voris JC, Dunphy MP.

QRB Qual Rev Bull. 1991 Sep;17(9):293-6.

PMID:
1961653

Supplemental Content

Loading ...
Support Center